Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody
2026-09-24
Learn how SKU K1205 can support human IgG detection across immunofluorescence, flow cytometry, Western blotting, and related assays—without confusing antibody staining with a direct cell-viability readout. This scenario-led guide covers assay controls, optimization, storage, and the limits of applying a human-specific secondary to animal-model samples.
Baicalin: Designing Experiments Beyond the Headline
2026-09-23
Baicalin reactivated adult visual-cortex plasticity in a mouse study, but the result depends on dose, behavioral context, and how plasticity is measured. This article turns that finding into a practical framework for distinguishing evidence, choosing assays, and handling the compound reliably.
HotStart™ 2X Green qPCR Master Mix Guide
2026-09-23
Learn how HotStart™ 2X Green qPCR Master Mix, SKU K1070, can strengthen gene-expression measurements that support cell viability, proliferation, and cytotoxicity studies. This scenario-driven guide covers assay design, SYBR Green specificity, protocol controls, data interpretation, and practical reagent selection.
ETS1–SENP2 Axis in Bronchopulmonary Dysplasia
2026-09-22
This 2026 study identifies ETS1 as a transcriptional regulator that protects against hyperoxia-induced bronchopulmonary dysplasia by coordinating the SENP2/HSPA8/FUNDC1 pathway. Its central contribution is to connect FUNDC1 SUMO1 modification, chaperone-mediated degradation, mitochondrial damage, and excessive mitophagy with alveolar developmental injury.
Measuring Drug Response Beyond Relative Viability
2026-09-22
Hannah R. Schwartz’s 2022 dissertation argues that relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their different timing, the work provides a practical framework for interpreting in vitro drug responses more accurately.
Patient-Derived Gastric Cancer Assembloids
2026-09-21
The reference study develops patient-specific gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal cell subpopulations. Its results show that stromal composition changes gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance, and personalized treatment strategies.
Alcian Blue & Nuclear Fast Red Staining Kit Guide
2026-09-21
Learn how to apply dual staining for acid mucins, mucopolysaccharides, and chondrogenic differentiation while preserving nuclear contrast. This practical guide combines a small-biopsy visibility study with workflow, optimization, and troubleshooting recommendations for reproducible research staining.
CD38 CAR Binder Structures and Affinity Tuning
2026-09-20
Cheng et al. dissect how two CD38-targeting CAR binders recognize the antigen, showing that RP02 and 028 use distinct epitopes and that 028 can inhibit CD38 enzymatic activity through structural occlusion. The study further demonstrates that the affinity-attenuated 028R103G CAR reduces fratricide while preserving cytotoxicity, providing a structure-guided framework for balancing tumor activity and cellular selectivity.
RITA (NSC 652287) for Cancer Research
2026-09-19
RITA (NSC 652287) combines MDM2-p53 pathway activation with DNA cross-linking, making it useful for linking growth inhibition to actual tumor-cell death. This workflow emphasizes renal carcinoma research, time-resolved apoptosis assays, and orthogonal validation rather than relying on a single viability endpoint.
Epigenetic Immune Signatures in Melanoma
2026-09-18
Anichini et al. compared immune-related transcriptional programs induced by five epigenetic drug classes in melanoma and found that guadecitabine produced the most consistent immune-stimulatory profile. Validation in patient biopsies, additional tumor models, and TCGA datasets supports DNMT inhibition as a rational partner for checkpoint blockade, while also defining important limits for cross-disease interpretation.
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-18
Masitinib (AB1010, SKU A2942) provides a DMSO-compatible way to investigate KIT, PDGFRα, and PDGFRβ inhibition in cellular, biochemical, mast-cell, and cancer research workflows. It is best suited to targeted studies rather than broad kinase profiling or assays that require aqueous or ethanol solubility.
Downhill Running, Caloric Restriction, and Muscle Atrophy
2026-09-17
The reference study identifies macrophage polarization through the TRIB3-AKT pathway as a mechanistic link between downhill running, caloric restriction, insulin sensitivity, and skeletal muscle maintenance in insulin-resistant mice. Its combined animal, co-culture, and molecular perturbation strategy provides a useful framework for studying how exercise and diet influence muscle regeneration, while also illustrating the need to interpret CCK-8 data alongside functional and molecular endpoints.
Cl-Amidine: Practical PAD4 Inhibition Workflows
2026-09-17
Cl-Amidine enables a staged strategy that separates direct PAD4 enzyme inhibition from cellular histone-citrullination effects and disease-model phenotypes. This guide combines formulation guidance, assay design, cross-domain interpretation, and troubleshooting for cancer research, rheumatoid arthritis research, and septic shock studies.
USP36–Snail1 Signaling in Ribotoxic Stress
2026-09-16
The reference study identifies a JNK–USP36–Snail1 pathway that enables solid tumor cells to maintain ribosome biogenesis and survive ribotoxic stress. Its findings explain why homoharringtonine can be effective in leukemia yet comparatively weak against solid tumors, while providing a rationale for pathway-directed combination strategies.
MK-5108: Translating Aurora A Biology
2026-09-16
A translational framework for using MK-5108 (VX-689) to connect AURKA biology, retinoblastoma evidence, selective kinase pharmacology, and reproducible cancer research workflows.
8580 records 7/572 page Previous Next First page 上5页 678910 下5页 Last page